Beam Therapeutics’ (BEAM) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Beam Therapeutics (NASDAQ:BEAM) in a report released on Monday morning,Benzinga reports. HC Wainwright currently has a $80.00 price objective on the stock. HC Wainwright also issued estimates for Beam Therapeutics’ Q1 2026 earnings at ($0.83) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.81) EPS, FY2026 earnings at ($3.30) EPS, FY2027 earnings at ($3.00) EPS, FY2028 earnings at ($1.91) EPS and FY2029 earnings at ($1.44) EPS.

A number of other research analysts have also weighed in on the company. Leerink Partners raised Beam Therapeutics from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $27.00 to $39.00 in a research note on Wednesday, November 6th. Royal Bank of Canada reduced their target price on Beam Therapeutics from $27.00 to $24.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 6th. Scotiabank began coverage on Beam Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $24.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $57.00 price objective on shares of Beam Therapeutics in a report on Monday, January 13th. Finally, Cantor Fitzgerald upgraded shares of Beam Therapeutics from a “neutral” rating to an “overweight” rating in a report on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $47.67.

Beam Therapeutics Trading Up 8.0 %

NASDAQ:BEAM opened at $27.82 on Monday. Beam Therapeutics has a 12-month low of $20.84 and a 12-month high of $49.50. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -15.81 and a beta of 1.92. The company’s 50-day moving average is $26.49 and its two-hundred day moving average is $25.77.

Beam Therapeutics (NASDAQ:BEAM) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.01). The firm had revenue of $14.30 million for the quarter, compared to analysts’ expectations of $14.52 million. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The business’s quarterly revenue was down 16.9% on a year-over-year basis. During the same period in the previous year, the company posted ($1.22) EPS. On average, equities research analysts forecast that Beam Therapeutics will post -4.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO John M. Evans sold 30,000 shares of the firm’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $26.75, for a total transaction of $802,500.00. Following the completion of the sale, the chief executive officer now directly owns 908,659 shares of the company’s stock, valued at approximately $24,306,628.25. This trade represents a 3.20 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christine Bellon sold 1,241 shares of Beam Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total transaction of $30,627.88. Following the sale, the insider now directly owns 102,968 shares in the company, valued at $2,541,250.24. This trade represents a 1.19 % decrease in their position. The disclosure for this sale can be found here. 4.20% of the stock is owned by corporate insiders.

Institutional Trading of Beam Therapeutics

Several large investors have recently modified their holdings of BEAM. Blue Trust Inc. increased its position in shares of Beam Therapeutics by 84.0% in the 3rd quarter. Blue Trust Inc. now owns 3,135 shares of the company’s stock worth $73,000 after purchasing an additional 1,431 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Beam Therapeutics by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,981 shares of the company’s stock valued at $75,000 after purchasing an additional 524 shares during the last quarter. Arcadia Investment Management Corp MI bought a new position in Beam Therapeutics in the third quarter worth about $98,000. KBC Group NV raised its position in shares of Beam Therapeutics by 103.2% during the 4th quarter. KBC Group NV now owns 4,143 shares of the company’s stock worth $103,000 after purchasing an additional 2,104 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Beam Therapeutics by 13.3% in the 3rd quarter. GAMMA Investing LLC now owns 4,620 shares of the company’s stock worth $113,000 after purchasing an additional 544 shares during the last quarter. 99.68% of the stock is currently owned by institutional investors and hedge funds.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.